PT-141 (bremelanotide) for women: what to know

Short version: “PT-141” and “bremelanotide” are two names for the same molecule, and there is exactly one form of it that carries FDA approval, sold as Vyleesi. That approval is narrow on purpose. It covers premenopausal women with a specific, distressing loss of sexual desire, and it explicitly does not cover postmenopausal women, men, or anyone looking to boost performance. What follows is who it is actually for, how it works, what the trials found, and what the label warns about, so you can have an accurate conversation with a licensed provider.

Is PT-141 FDA-approved for women?

Yes, but only in one form and only for one narrow group of women. Bremelanotide, the compound sold in the research and biohacking community as PT-141, is the active ingredient in a prescription medicine called Vyleesi. Vyleesi is FDA-approved: the agency cleared it on June 21, 2019 under new drug application 210557 (FDA approval package, 2019; FDA, June 21, 2019). It is not a controlled substance. The important nuance for midlife women is that “PT-141 is approved” and “the version you can buy online is approved” are not the same statement. The approval attaches to the branded product and its single labeled use, described in the next section, and much of what is marketed loosely online as “PT-141” sits outside that approval.

Which women is Vyleesi actually approved for?

Vyleesi’s approval is deliberately narrow: premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The label states that “VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)” (VYLEESI prescribing information, FDA, 2019). Each word narrows it. “Acquired” means the low desire is new: the woman had a normal level of sexual interest before and then lost it, rather than never having had it. “Generalized” means it happens across the board, regardless of the partner, the situation, or the type of stimulation. And it only counts as HSDD if the low desire causes marked distress or interpersonal difficulty and is not better explained by another medical or psychiatric condition, by relationship problems, or by the effects of a medication or other substance (FDA, June 21, 2019). That last clause matters in midlife, where low desire often has more than one driver. The label also carries explicit limitations of use: “VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men” and “is not indicated to enhance sexual performance” (VYLEESI prescribing information, FDA, 2019).

How does bremelanotide (PT-141) work?

Bremelanotide works through the brain’s melanocortin system rather than through blood flow. Chemically it is a synthetic peptide, a lab-made analog of a natural signaling hormone, and the label describes it plainly: “Bremelanotide is a melanocortin receptor (MCR) agonist,” with activity at the MC1 and MC4 receptors considered most relevant (VYLEESI prescribing information, FDA, 2019). That is a different mechanism from the erectile-dysfunction drugs people often compare it to: sildenafil and tadalafil act on blood vessels, while bremelanotide acts on central pathways thought to be involved in sexual desire. Honesty requires a caveat here, because the label itself notes that the exact way the drug improves desire and the related distress is not fully understood. In practice it is used on demand: a 1.75 mg dose is self-injected under the skin of the abdomen or thigh at least 45 minutes before anticipated sexual activity, not taken on a daily schedule. In the phase 3 trials most women used it only two or three times a month, and no more than about once a week, which fits that on-demand design rather than a continuous-dosing one (FDA, June 21, 2019).

How well does PT-141 work, and what did the trials show?

In two large phase 3 trials, bremelanotide produced statistically significant but modest improvements in desire and distress compared with placebo. The trials, known as the RECONNECT studies (Studies 301 and 302), randomized 1,267 premenopausal women with acquired, generalized HSDD to 1.75 mg on demand or placebo over a 24-week double-blind period (Kingsberg et al., Obstet Gynecol, 2019). Both co-primary endpoints favored the drug: the change in the desire domain of the Female Sexual Function Index improved by an integrated 0.35 points (P < .001), and distress about low desire, measured by item 13 of the Female Sexual Distress Scale, fell by an integrated 0.33 points (P < .001) (Kingsberg et al., 2019). Those are real, repeatable effects, but the effect sizes were small to modest (about 0.39 for desire and 0.27 for distress), which is the honest way to set expectations: on average the drug helped more than placebo, not dramatically, and many women did not respond. The trial authors reported that most side effects were mild or moderate.

What are the side effects and safety warnings?

The most common side effect by a wide margin is nausea, and the label carries specific cardiovascular cautions. In the phase 3 trials nausea occurred in 40.0% of women on bremelanotide versus 1.3% on placebo, and 8.1% stopped treatment because of it (Kingsberg et al., Obstet Gynecol, 2019). Other common reactions were flushing (20.3%), injection-site reactions (13.2%), headache (11.3%), and vomiting (4.8%) (VYLEESI prescribing information, FDA, 2019). Each dose causes a transient rise in blood pressure and a small fall in heart rate that usually resolve within about 12 hours, which is why the drug is contraindicated in women with uncontrolled hypertension or known cardiovascular disease. Repeated use can cause focal hyperpigmentation, darkened patches of skin or gums that may not fully reverse, and this is more likely with frequent dosing. The label also flags an interaction with oral naltrexone. To limit these risks, dosing is capped at one injection per 24 hours and no more than eight per month, and providers are advised to stop the drug after eight weeks if it is not helping (FDA, June 21, 2019).

Is PT-141 approved for postmenopausal women or for general libido?

No. This is the single most important point for a midlife audience, because it is also the most commonly misrepresented. The FDA approval does not cover postmenopausal women, does not cover men, and does not cover using the drug to enhance sexual performance or general libido; the label lists all three as limitations of use (VYLEESI prescribing information, FDA, 2019). Much of the “PT-141” sold online is marketed for exactly those excluded uses, and those versions have not been through the FDA approval process. If you are postmenopausal, or if your interest is broadly “more libido” rather than the specific, distressing, acquired loss of desire the label describes, then the approved product does not apply to your situation, and a provider is the right person to explain what, if anything, is a reasonable option instead. For women in perimenopause who are still premenopausal, candidacy is an individual clinical judgment, not a given.

Vyleesi (bremelanotide / PT-141) at a glance

The table below summarizes the approved product’s key facts so you can compare them against whatever you read elsewhere.

How do you find out whether it is right for you?

The honest next step is a conversation with a licensed provider, not an online purchase. Because the approved use is so specific and the safety cautions are concrete, whether bremelanotide fits depends on details a form cannot capture: your menopausal stage, your blood pressure and cardiovascular history, the other medications you take, and whether your experience actually matches the acquired, generalized, distressing pattern the label describes. A responsible provider will also weigh the modest average benefit against the side-effect profile and may conclude it is not the right choice, which is exactly how a candidacy decision is supposed to work. That is different from buying an unapproved product online for a use the label excludes. Low desire in midlife often has several contributors at once, from sleep and mood to relationship strain and other medications, so a careful evaluation is also a chance to look at the whole picture rather than reaching for a single injection as a fix. If cost is part of the decision, PeptideAgent’s Vyleesi cost page breaks the price down by channel, from the manufacturer savings program to telehealth.

Sources and further reading

Every clinical and regulatory statement on this page traces to a primary source, listed here so you can verify it directly.

• VYLEESI (bremelanotide injection) prescribing information (FDA, 2019)
• VYLEESI approval package, NDA 210557 (FDA, 2019)
• FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women (June 21, 2019)
• Kingsberg et al., Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstet Gynecol, 2019), full text
• Kingsberg et al., 2019, PubMed record
• Vyleesi (bremelanotide) FDA approval history (Drugs.com)
• RECONNECT Study 301 registration, NCT02333071 (ClinicalTrials.gov)